Skip to main content

Table 2 Characteristics of patients with systemic sclerosis

From: Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors

Disease characteristic N = 49
Systemic sclerosis subset, number (percentage)  
   Diffuse cutaneous systemic sclerosis 4 (8%)
   Limited cutaneous systemic sclerosis 45 (92%)
Disease duration, years 6 (2–12)
Raynaud phenomenon duration, years 11 (6–25)
Antibody, number (percentage)  
   Scl70 (topoisomerase 1) 4 (8%)
   Centromere 22 (45%)
   Nuclear ribonucleoprotein 2 (4%)
   Antinuclear antibodies, not specified 17 (35%)
   None 4 (8%)
EScSG disease activity index 0.5 (0.5–1.5)
Medsger severity scale score 6.0 (4.5–7.0)
Modified Rodnan skin score 7.0 (4.5–14.0)
Prednisolone use, number (percentage)  
   None 28 (57%)
   Former 13 (27%)
   Current 8 (16%)
Cumulative prednisolone dose, grams 3.6 (1.9–16.1)
Immunosuppressive agents, number (percentage)  
Never used 25 (51%)
Former or current users 24 (49%)
   Methotrexate  
Current 12
Former 7
   Cyclophosphamide  
Current 2
Former 4
   Azathioprine  
Current 3
Former 3
   Cyclosporin  
Current 0
Former 1
  1. Unless stated otherwise, data are expressed as mean ± standard deviation when normally distributed and as median (interquartile range) when non-normally distributed. EScSG, European Scleroderma Study Group.